Biologics developers are caught in a paradox: demand for therapies is climbing, but the industry faces constant pressure to cut costs and move faster.

Q1 2026 Management View CEO Jeffrey Harmening emphasized the company's focus on navigating significant change, including the Yoplait divestiture and the Whitebridge acquisition, while reaffirming ...

The appointments of Patrick Donoghue, Kendall Bazan and Andrew Hurd mark the next chapter for Groundfloor Lending.

RCM raises $14m in placement; heavy rare earth and niobium discovery at Araxá; and copper ... Read More The post Resources ...

Malaysian automotive players remain wary of the sector's outlook for the year ahead, amid heightened price competition and ...

Cryptocurrency exchanges are dynamic, volatile, and highly unpredictable, and hence, traders use factors that give them ...

Hybrid crypto signals offer a new frontier in the trading of cryptocurrencies through combining the speed and accuracy of ...

Boardroom speaks with the CEO of music fintech company Stem to learn how she’s reshaping what independence looks like in ...

United is launching flights to 15 cities served by Spirit Airlines, indicating that there will be alternatives for customers ...

The e-tailing giant has long-term ambitions to become a full-fledged fintech player. But it has lost out on UPI payments to ...

Legal market is keeping scandals in check, say stakeholders. Don't expect those not regulated by the state to do the same ...

Butterfly's growth hinges on expanding software revenue with upcoming launches like Compass AI and Home Care ...